New Migraine Treatment Prevents Pain Progression


AXS-07 showed statistical significance for migraine pain freedom at 90 minutes, and at every time point after.

Stewart Tepper, MD

Stewart Tepper, MD

This article, "AXS-07 Meets Primary End Points, Halts Migraine Pain Progression," was originally published in NeurologyLive.

A new drug may soon help eliminate migraine pain and prevent the progression of migraine pain intensity.

In the INTERCEPT phase 3 trial, AXS-07 met all co-primary end points and showed efficacy in preventing the progression of migraine pain beyond mild intensity while significantly reducing the use of rescue medication.

AXS-07’s formulation consists of both MoSEIC meloxicam and rizatriptan and it is administered in tablet form to provide an enhanced rate of absorption of meloxicam.

INTERCEPT was a double-blind, placebo-controlled trial that included 302 patients randomized 1:1 to treat a single migraine attack with a single dose of AXS-07 (20 mg meloxicam/10 mg rizatriptan), or placebo, at the earliest sign of migraine pain, while the pain intensity was mild.

The investigators sought primary outcome measures observed included percentage of patients reporting headache pain freedom at 2 hours and percentage of patients with absence of most bothersome symptoms.

They also sought co-primary end points of pain freedom and freedom from the most bothersome symptom.

There were a statistically significantly greater percentage of patients achieving pain freedom compared to placebo (32.6% versus 16.3%, respectively; P = .002), as well as freedom from the most bothersome symptom (43.9% versus 26.7%, respectively; P = .003), 2 hours after dosing.

Between 2-24 hours after dosing, freedom of pain progression occurred in 73.5% of AXS-07 patients compared with 47.4% of placebo patients (P <.001).

The drug showed significant results on both co-primary end points but was also numerically superior to placebo in a multitude of other end points.

Pain freedom and most bothersome symptom freedom was achieved as early as 30 minutes in patients who received AXS-07. Additionally, the drug achieved statistical significance for migraine pain freedom at 90 minutes (P = .003) and at every time point after.

Sustained pain freedom from 2-24 hours after dosing was experienced by 22.7% and 12.6% of patients treated with AXS-07 and placebo, respectively (P = .030). Similar sustained pain freedom from 2-48 hours after dosing was seen in both AXS-07 and placebo patients as well (20.5% vs 9.6%; P = .013).

While the drug prevented progression of migraine pain intensity, rescue medication was used by 15.3% of AXS-07 patients compared to 42.2% of placebo patients over 24 hours (P <.001).

Researchers observed functional and global improvement as well, noting that 52.4% of AXS-07 patients were very much or much improved compared to 27.7% of placebo patients (P <.001) on the Patient Global Impression of Change (PGI-C) scale.

The drug was generally safe and well tolerated with no reports of serious adverse events (AEs) throughout the trial. Somnolence, dizziness and paresthesia, all of which occurred in less than 5%, were among the most commonly reported adverse events.

“These results, coupled with previous clinical data showing superiority of AXS-07 over an active comparator, provide clinical evidence that this synergistic, multi-mechanistic approach and the rapid absorption of AXS-07 may translate to important benefits for a wide range of patients,” Stewart Tepper, MD, professor of neurology, Geisel School of Medicine, Dartmouth University, said in a statement. “As clinicians continue to seek options for their patients with improved efficacy over currently available therapies, AXS-07 may offer an important new treatment for this disabling condition.”

Related Videos
Getting Black Men Involved in Their Health Care, Clinical Research
Patient Involvement in Advanced HF Treatment, with Ashley Malliett, DMSc, MPAS, PA-C
Aaron Henry, PA-C, MSHS: Regaining Black Male Patient Trust in the Doctor's Office
How to Adequately Screen for and Treat Cognitive Decline in Primary Care
James R. Kilgore, DMSc, PhD, PA-C: Cognitive Decline Diagnostics
What Should the American Academy of Physician Associates Focus on in 2025?
Danielle O'Laughlin, PA-C, MS: Navigating Long-Term Risks, Family Planning in PCOS
© 2024 MJH Life Sciences

All rights reserved.